Citations

Clear

2303 citation(s) found for "Yu, Edward".

Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).
Rizvi, Naiyer A. , Patnaik, Amita , Balmanoukian, Ani Sarkis, Blumenschein, George R. , Gubens, Matthew A. , Papadopoulos, Kyriakos P. , Lubiniecki, Gregory M., Zhang, Jin , Niewood, Michelle, Emancipator, Kenneth , Dolled‐Filhart, Marisa, Hanson, Mary E. , Hui, Rina , Garon, Edward B. , Gandhi, Leena , Leighl, Natasha B , Goldman, Jonathan W. , Eder, Joseph P. , Johnson, Elizabeth Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8007-8007

10.1200/jco.2014.32.15_suppl.8007 Get It

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rec
Lenz, Heinz‐Josef , Innocenti, Federico , Mahoney, Michelle R., O’Neil, Bert H. , Polite, Blasé N. , Höchster, Howard S. , Atkins, James N., Goldberg, Richard M. , Schilsky, Richard L. , Blanke, Charles D. , ECOG, Cancer and Leukemia Group B (Alliance), SWOG, and, Venook, Alan P. , Niedzwiecki, Donna , Shaw, James Edward , Mayer, Robert J. , Bertagnolli, Monica M. , ECOG, Cancer and Leukemia Group B (Alliance), SWOG, and

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA3-LBA3

10.1200/jco.2014.32.15_suppl.lba3 Get It

Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refr
Bensinger, William, Novitzky, Nicolás , McDonald, Andrew , Gutierrez, Martin , Libby, Edward N., Thompson, John E., Bexon, Alice, Barranco, Charles, Taylor, Catherine , Dondero, Richard, Browne, Leslie J., Kurman, Michael R., Lust, John A., Craig, Michael , Siegel, David S. , Rhee, Frits van

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS8616-TPS8616

10.1200/jco.2014.32.15_suppl.tps8616 Get It

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
Yoon, Harry H. , Bendell, Johanna C. , Braiteh, Fadi S., Firdaus, Irfan , Philip, Philip Agop, Cohn, Allen Lee, Lewis, Nancy , Anderson, D. Mark , Arrowsmith, Edward, Schwartz, Jonathan D. , Xu, Yihuan, Koshiji, Minori, Anderson, Daniel M., Alberts, Steven R. , Wainberg, Zev A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4004-4004

10.1200/jco.2014.32.15_suppl.4004 Get It

Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.
Buckner, Jan C. , Pugh, Stephanie L. , Shaw, Edward G. , Barger, Geoffrey, Coons, Stephen W., Ricci, Peter E. , Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , Brachman, David, Schultz, Christopher J. , Bahary, Jean-Paul , Fisher, Barbara J., Kim, Harold , Murtha, Albert , Curran, Walter J. , Gilbert, Mark R. , Suh, John H. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2000-2000

10.1200/jco.2014.32.15_suppl.2000 Get It

Cardiovascular magnetic resonance imaging compared to echocardiogram for detecting doxorubicin-induced cardiotoxicity.
Rasool, Haleem J. , Tak, Tahir , Gill, Paula, Novotny, James Edward, Jaekel, Camilla, Elkhatib, Rifat T. , Ticku, Jonathan, Boland, Emily R, Marshall, Angus, Marshall, Angus

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 1068-1068

10.1200/jco.2014.32.15_suppl.1068 Get It

Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).
Sehdev, Amikar, Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , Mahoney, Michelle R., Polite, Blasé N. , Höchster, Howard S. , Atkins, James N., Goldberg, Richard M. , Schilsky, Richard L. , Blanke, Charles D. , O’Neil, Bert H. , SWOG, Cancer and Leukemia Group B (Alliance) and, Niedzwiecki, Donna , Venook, Alan P. , Shaw, James Edward , Mayer, Robert J. , Bertagnolli, Monica M. , SWOG, Cancer and Leukemia Group B (Alliance) and

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 638-638

10.1200/jco.2018.36.4_suppl.638 Get It

638 Background: Colorectal cancer (CRC) is a heterogeneous disease with distinct molecular subtypes in part based on RAS mutational status. It is plausible that RAS mutations are differentially distributed between CC and AA and may contribute to poor outcomes in AAs with CRC. Methods: We did a retrospective analysis of CALGB/SWOG 80405 trial patients. We divided the entire cohort into 2 groups: a) Common RAS: mutation in KRAS exon 2, codon 12 or 13; b) Extended RAS: any NRAS mutations or mutation in KRAS except those listed above. We then analyzed these two subgroups for association between RAS mutations and race (3 categories: Caucasian, AA, Others) using chi-square test for univariate analyses and logistic regression for multivariate analysis. We also analyzed the effect of extended RAS testing on prognosis of metastatic CRC by estimating the overall survival (OS) using Kaplan-Meier method and 95% confidence interval (CI). Cox proportional-hazard model was used for multivariate analyses. Results: There were 1729 CRC patients in common RAS group of which 357 (20.6%) had mutations present. Extended RAS group had 621 patients of which 95 (15.5%) had mutations present. There was no significant difference in the rate of common RAS mutations between CC and AA (20.5% vs. 24%, p=0.22). However, extended RAS mutations were significantly more in AA as compared to CC (25% vs. 14%, p=0.02). Multivariate analysis adjusted for age, gender, prior adjuvant chemotherapy and pelvic radiation confirmed higher odds of extended RAS mutation in AA compared to CC (adjusted OR 1.12; 95% CI 1.01-1.23; p=0.02). The median OS in patients with an extended RAS mutation was shorter as compared to those without extended RAS mutation (25.3 vs. 31.9 months; HR 1.26; 95% CI 0.99-1.62; p=0.05). Multivariate analyses adjusted for age, gender, race, prior adjuvant chemotherapy and pelvic radiation showed a trend towards longer OS in patients without extended RAS mutation as compared those with extended RAS mutation (adjusted HR= 1.24, 95% CI, 0.97-0.1.58, p=0.08). Conclusions: Extended RAS mutations are significantly more common in AA as compared to CC. Additionally, presence of extended RAS mutation may confer a poor prognosis in CRC patients.
Improvements in treatment planning calculations motivated by tightening IMRT QA tolerances
Stambaugh, Cassandra , Gagneur, Justin D., Uejo, Arielle, Clouser, Edward , Ezzell, Gary A., Gagneur, Justin, Ezzell, Gary, Clouser, Edward Lee

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 1, 2019 | Volume: 20 | Issue: 1 | Pages: 250-257

10.1002/acm2.12524 | PMID 30599085 Get It

AbstractImplementing tighter intensity modulated radiation therapy (IMRT) quality assurance (QA) tolerances initially resulted in high numbers of marginal or failing QA results and motivated a number of improvements to our calculational processes. This work details those improvements and their effect on results. One hundred eighty IMRT plans analyzed previously were collected and new gamma criteria were applied and compared to the original results. The results were used to obtain an estimate for the number of plans that would require additional dose volume histogram (DVH)‐based analysis and therefore predicted workload increase. For 2 months and 133 plans, the established criteria were continued while the new criteria were applied and tracked in parallel. Because the number of marginal or failing plans far exceeded the predicted levels, a number of calculational elements were investigated: IMRT modeling parameters, calculation grid size, and couch top modeling. After improvements to these elements, the new criteria were clinically implemented and the frequency of passing, questionable, and failing plans measured for the subsequent 15 months and 674 plans. The retrospective analysis of selected IMRT QA results demonstrated that 75% of plans should pass, while 19% of IMRT QA plans would need DVH‐based analysis and an additional 6% would fail. However, after applying the tighter criteria for 2 months, the distribution of plans was significantly different from prediction with questionable or failing plans reaching 47%. After investigating and improving several elements of the IMRT calculation processes, the frequency of questionable plans was reduced to 11% and that of failing plans to less than 1%. Tighter IMRT QA tolerances revealed the need to improve several elements of our plan calculations. As a consequence, the accuracy of our plans have improved, and the frequency of finding marginal or failing IMRT QA results, remains within our practical ability to respond.
Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission
Husseini, Nada El , Sheng, Shubin , Schulte, Phillip J. , Xian, Ying , Goldstein, Larry B. , Fonarow, Gregg C. , Smith, Eric Edward , Ju, Christine , Schwamm, Lee H. , Hernandez, Adrian F.

Mayo Clinic

Stroke | December 26, 2018 | Volume: 49 | Issue: 12 | Pages: 2896-2903

10.1161/strokeaha.118.022011 | PMID 30571413 Get It

Background and Purpose— Kidney dysfunction is common among patients hospitalized for ischemic stroke. Understanding the association of kidney disease with poststroke outcomes is important to properly adjust for case mix in outcome studies, payment models and risk-standardized hospital readmission rates. Methods— In this cohort study of fee-for-service Medicare patients admitted with ischemic stroke to 1579 Get With The Guidelines-Stroke participating hospitals between 2009 and 2014, adjusted multivariable Cox proportional hazards models were used to determine the independent associations of estimated glomerular filtration rate (eGFR) and dialysis status with 30-day and 1-year postdischarge mortality and rehospitalizations. Results— Of 204 652 patients discharged alive (median age [25th–75th percentile] 80 years [73.0–86.0], 57.6% women, 79.8% white), 48.8% had an eGFR ≥60, 26.5% an eGFR 45 to 59, 16.3% an eGFR 30 to 44, 5.1% an eGFR 15 to 29, 0.6% an eGFR <15 without dialysis, and 2.8% were receiving dialysis. Compared with eGFR ≥60, and after adjusting for relevant variables, eGFR <45 was associated with increased 30-day mortality with the risk highest among those with eGFR <15 without dialysis (hazard ratio [HR], 2.09; 95% CI, 1.66–2.63). An eGFR <60 was associated with increased 1-year poststroke mortality that was highest among patients on dialysis (HR, 2.65; 95% CI, 2.49–2.81). Dialysis was also associated with the highest 30-day and 1-year rehospitalization rates (HR, 2.10; 95% CI, 1.95–2.26 and HR, 2.55; 95% CI, 2.44–2.66, respectively) and 30-day and 1-year composite of mortality and rehospitalization (HR, 2.04; 95% CI, 1.90–2.18 and HR, 2.46; 95% CI, 2.36–2.56, respectively). Conclusions— Within the first year after index hospitalization for ischemic stroke, eGFR and dialysis status on admission are associated with poststroke mortality and hospital readmissions. Kidney function should be included in risk-stratification models for poststroke outcomes.
Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report
Kroenke, Kurt , Argoff, Charles E. , Canlas, Bernard, Covington, Edward C. , Frank, Joseph W. , Haake, Karl J, Hanling, Steven , Hooten, W. Michael , Kravitz, Richard L. , Krebs, Erin E. , Stanos, Steven P., Alford, Daniel P. , Kertesz, Stefan G. , Sullivan, Mark Daniel

Mayo Clinic

Pain Medicine | December 15, 2018 | Volume: 20 | Issue: 4 | Pages: 724-735

10.1093/pm/pny307 | PMID 30690556 Get It